Answers are grounded in this paper and cite their sources.
Finds colchicine does not reduce composite cardiovascular events in acute myocardial infarction patients, highlighting limited long-term secondary prevention benefits.
Among patients who had myocardial infarction, treatment with colchicine, when started soon after myocardial infarction and continued for a median of 3 years, did not reduce the incidence of the composite primary outcome (death from cardiovascular causes, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization). (Funded by the Canadian Institutes of Health Research and others; CLEAR ClinicalTrials.gov number, NCT03048825.).
No takes yet. Share an insight, caveat, or question.
Jolly et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: